Conflict of interest, journal review, and publication policy.
In summary, the journal editors' effort to restore faith in science by financial disclosure has been inadequate to the task. The editors could improve matters by demanding access to the raw data supporting claims for product safety and effectiveness. The recent emphasis on a detailed clinical trials registry anteceding the trial is clearly a breakthrough. The mandated clinical trial registries that include outcome data are even better. How well this works in terms of detailed public knowledge remains to be seen.
Klein
Donald F
DF
Phyllis Green and Randolph Cowen Institute for Pediatric Neuroscience, NYU Child Study Center, NYU Medical Center, New York, NY, USA.
Glick
Ira D
ID
D022126:Access to Information / Q000941:ethics / Q000331:legislation & jurisprudence; D016265:Conflict of Interest / Q000191:economics / Q000331:legislation & jurisprudence; D003627:Data Interpretation, Statistical; D030881:Disclosure / Q000941:ethics / Q000592:standards / Q000639:trends; D004345:Drug Industry / Q000191:economics / Q000941:ethics / Q000639:trends; D006801:Humans; D009480:Neuropharmacology / Q000191:economics / Q000941:ethics* / Q000639:trends; D017712:Peer Review, Research / Q000941:ethics* / Q000592:standards / Q000639:trends; D010506:Periodicals as Topic / Q000191:economics / Q000941:ethics* / Q000639:trends; D015203:Reproducibility of Results; D015871:Scientific Misconduct